Preparation, Optimization and Toxicity Evaluation of (SPION-PLGA) ±PEG Nanoparticles Loaded with Gemcitabine as a Multifunctional Nanoparticle for Therapeutic and Diagnostic Applications

authors:

avatar Nima Hamzian a , avatar Maryam Hashemi b , avatar Mahdi Ghorbani c , avatar Mohammad Hossein Bahreyni Toosi d , * , avatar Mohammad Ramezani e

Department of Medical Physics, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Biomedical Engineering and Medical Physics Department, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Medical Physics Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Iranian Journal of Pharmaceutical Research : IJPR: Vol.16, issue 1; 8-21
article type: Original Article
received: October , 2015
accepted: June , 2016
DOI: https://doi.org/10.22037/ijpr.2017.1964

how to cite: Hamzian N, Hashemi M, Ghorbani M, Bahreyni Toosi M H, Ramezani M. Preparation, Optimization and Toxicity Evaluation of (SPION-PLGA) ±PEG Nanoparticles Loaded with Gemcitabine as a Multifunctional Nanoparticle for Therapeutic and Diagnostic Applications. Iran J Pharm Res. 2017;16(1):e124914. https://doi.org/10.22037/ijpr.2017.1964.

Abstract

The aim of this study was to develop a novel multifunctional nanoparticle, which encapsulates SPION and Gemcitabine in PLGA ± PEG to form multifunctional drug delivery system. For this aim, super paramagnetic iron oxide nanoparticles (SPIONs) were simultaneously synthesized and encapsulated with Gemcitabine (Gem) in PLGA ± PEG copolymers via W/O/W double emulsification method. Optimum size and encapsulation efficiency for radiosensitization, hyperthermia and diagnostic applications were considered and the preparation parameters systematically were investigated and physicochemical characteristics of optimized nanoparticle were studied. Then SPION-PLGA and PLGA-Gem nanoparticles were prepared with the same optimized parameters and the toxicity of these nanoparticles was compared with Gemcitabine in human breast cancer cell line (MCF-7). The optimum preparation parameters were obtained with Gem/polymer equal to 0.04, SPION/polymer equal to 0.8 and 1% sucrose per 20 mg of polymer. The hydrodynamic diameters of all nanoparticles were under 200 nm. Encapsulation efficiency was adjusted between 13.2% to 16.1% for Gemcitabine and 48.2% to 50.1% for SPION. In-vitro Gemcitabine release kinetics had controlled behavior. Enhancement ratios for PLGA-Gem and SPION-PLGA-Gem at concentration of nanoparticles equal to IC50 of Gemcitabine were 1.53 and 1.89 respectively. The statistical difference was significant (p-value = 0.006 for SPION-PLGA-Gem and p-value = 0.015 for PLGA-Gem compared with Gemcitabine). In conclusion, we have successfully developed a Gemcitabine loaded super paramagnetic PLGA-Iron Oxide multifunctional drag delivery system. Future work includes in-vitro and in-vivo investigation of radiosensitization and other application of these nanoparticles.

Introduction

Gemcitabine (2ʹ,2ʹ-difluoro-2ʹDeoxycytidine) as a chemotherapy agent is a deoxycytidine analog with similar structure to Cytarabine. Gemcitabine (Gem) as a single agent or in combination with other agents is effective for treatment of various solid tumors and a number of hematologic malignancies (1, 2). Gemcitabine has chemical instability, poor cell uptake and a very short half-life in plasma. These properties lead to use of higher doses and result in systemic toxicity which is known as a side effect of this chemotherapy drug (3, 4).

Magnetic nanoparticles have been investigated as carriers for targeted drug delivery to overcome this great disadvantage (5-8). This is due to their high magnetic responsiveness, biodegradability, biocompatibility, high delivery efficiency and potential targeting function (9-11). Moreover, iron oxide nanoparticles are the only magnetic nanoparticles approved for clinical application by the US Food and Drug Administration (FDA) (12). In a number of studies, Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) have been used for diagnostic and therapeutic applications such as magnetic resonance imaging (MRI) by contrast agents (13), magnetic hyperthermia in cancer treatment (14) and radiosensitization in radiotherapy (15). In addition, drugs can be loaded onto magnetic nanoparticles for targeted therapy with the aid of an external magnet (5-7). For this purpose, magnetic Fe3O4 nanoparticles are firstly prepared and then are encapsulated in copolymers.

Recently, the use of biodegradable copolymers of poly lactic-co-glycolic acid (PLGA) for delivery of chemotherapy drugs has increased the efficiency in treatment of tumors in a wide range of cancer types (3, 4). PLGA has been approved by FDA for human use (16). The advantages of this polymer are biodegradability, biocompatibility, ease of accumulation within the tumor, rapid clearance from biological systems and high efficiency of drug delivery (17-19). PLGA is strongly hydrophobic, which causes limitations in its use in practical drug formulations. Poly (ethylene glycol) (PEG) is a non-toxic, water-soluble, and biocompatible polymer. Block copolymers consisting of hydrophobic polyester and a hydrophilic PEG segment have gained increasing attention due to their biodegradability, biocompatibility, and tailor-made properties (20-23). Previous studies have shown that nanoparticles made of PEG-PLGA exhibit long-circulation properties, in-vivo. This property is because the surface of hydrophilic molecular chains of PEG cannot be recognized and phagocytized by mono-nuclear phagocyte systems (20, 21).

The aim of this study is to develop a novel drug delivery system in which Gemcitabine and SPION are encapsulated in PLGA ± PEG to form a multifunctional nanoparticle. For this purpose, firstly the incorporation of SPION and Gemcitabine into PLGA ± PEG nanoparticles was optimized via W/O/W double emulsification method. The preparation parameters of (SPION-PLGA-Gem) ± PEG were systematically investigated.

Therefore, using the optimized formulation, nanoparticles could be produced with several expected characteristics, such as optimum encapsulation efficiency and size, with the aim of radiosensitization, hyperthermia and diagnostic applications. Then SPION-PLGA and PLGA-Gem nanoparticles were prepared with the same preparation method of the SPION-PLGA-Gem and physicochemical properties and in-vitro cytotoxicity of the nanoparticles was characterized on MCF7 human breast cancer cell line.

Experimental

Materials

Ferric chloride hexahydrate (FeCl3- 6H2O, 98%), ferrous chloride tetrahydrate (FeCl2- 4H2O), and ammonium hydroxide (25% w.t) were purchased from Fluka (Buchs, Switzerland). Poly(d,l-lactic-co-glycolic acid) (PLGA) (Average Mw: 17,000-35,000; lactic acid: glycolic acid = 50:50), Poly (ethylene glycol) (PEG) (Average Mw: 9000) and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were obtained from Sigma-Aldrich (Munich, Germany). Gemcitabine hydrochloride was purchased from Euroasia Co., Ltd. (Delhi, India). Roswell Park Memorial Institute (RPMI) 1640 medium, fetal bovine serum (FBS) and trypsin were purchased from GIBCO (Gaithersburg, USA Darmstadt, Germany). Polyvinyl alcohol (PVA, 87-89% hydrolyzed, average MW = 88,000-97,000) and other solvent and chemical agents were procured from Merck (Germany) without further purification. Water used in the experiments was deionized and filtered (Milli-Q Academic, Millipore, France).

Synthesis of SPIONs

SPIONs were synthesized using a co-precipitation method (24). Briefly, 450 mL of deionized water was stirred mechanically for 15 min under a nitrogen gas at room temperature to remove O2 from solution. Then 0.19 mg FeCl2 (4H2O) and 0.486 mg FeCl3 (6H2O) were added to the vigorously stirred water and 250 mg of oleic acid was quickly added to the previous reaction mixture and the product container was placed in a water bath (75-80 ˚C). After 15 min, 1.35 mL of NH4OH was added during one minute and argon gas flow was discontinued. After about 30 min, SPIONs were deposited. The product was washed three times with deionized water and the black precipitate was separated using a permanent magnet and lyophilized.

Preparation of (SPION- PLGA-Gem) ± PEG nanoparticles

Double emulsion method (W1/O/W2) was used for preparation of SPION-PLGA-Gem nanoparticles. Briefly, 1 mL of SPION suspension in chloroform was mixed with 1 mL of the organic solution of the polymer (PLGA ± PEG) in dichloromethane. Then, 0.2 mL solution of Gem in deionized water was added to the organic phase, and the mixture was emulsified by probe sonication (Fisons Instruments Ltd,. Crawley, UK) for 1 min (0.6 Hz frequency, 90 amplitude) (W1/O). The primary water-in-oil (W/O) emulsion was added drop wise to 8 mL of ice-cold aqueous PVA solution (5%, W/V) and emulsified for 10 min using a probe sonicator (W1/O/W2). To evaporate the organic solvent, the resulted solution was diluted in 10 mL aqueous PVA solution (0.1%, w/v) under stirring at room temperature overnight. Then the nanoparticles were collected by centrifugation at 14000 rpm for 15 min and washed three times with deionized water. Finally, the products were freeze-dried and the dry samples were filled with N2 gas and stored in a freezer for further use.

In this study, the effect of various processing parameters on the mean diameter of nanoparticles or/and encapsulation efficiency (EE) were evaluated. These parameters included amount of sucrose as cryoprotector (0%, 1% and 3% per 20 mg of polymer), amount of PEG (0% or 20% by weight of the polymer), concentration of SPION (2, 4 and 10 mg per 1 mL of chloroform) and concentration of Gemcitabine hydrochloride (1 or 2 mg per 200 μL of deionized water, equivalent to Gem/Polymer of 0.04 and 0.08). The technical parameters of the preparation and the volume fractions were selected based on previous experiences in this field. The amount of polymer (PLGA ± PEG) was kept constant (25 mg per 1 mL of dichloromethane).

Preparation of SPION-PLGA, PLGA-Gem and PLGA nanoparticles

The PLGA-Gem nanoparticles were prepared using similar method to that used for SPION-PLGA-Gem nanoparticles however there was no SPION in the oil phase. Furthermore SPION-PLGA nanoparticles were prepared with the same method except that there was no Gemcitabine in W1 phase.

For the evaluation of toxicity, PLGA nanoparticles were prepared in the same manner as the control group.

Nanoparticles characterization

Loading content and encapsulation efficiency

Loading and encapsulation efficiency of Gemcitabine were determined in triplicate using a UV-Vis spectrophotometer (Shimatzu, Tokyo, Japan) by an excitation wavelength, λ = 268 nm.

Regarding SPION-PLGA-Gem formulation, since the SPION has absorption in this range of wavelengths; the SPION should be removed from SPION-PLGA-Gem formulation. For this purpose, 5 mg of SPION- PLGA-Gem nanoparticles was dissolved in 1 mL of acetonitrile and mixed with 4 mL PBS (pH 7.4). The mixture was incubated for 30 min at room temperature and then centrifuged at 14,000 rpm for 20 min. The concentration of Gemcitabine in supernatant was determined by the UV-Vis spectrophotometer. The accuracy of separation was confirmed by comparing the absorptions of solution at wavelengths of 268 and 320 nm. For PLGA-Gem nanoparticles, 1 mg NPs was dissolved in 1 mL dimethylsulfoxide (DMSO) and the concentration of Gemcitabine in solution was analyzed using UV–visible spectrophotometer at 268 nm.

Loading contents and encapsulation efficiencies were calculated using the following formulas:

Loading contents (%) = (Drug weight in the nanoparticles /Weight of nanoparticles) × 100

Encapsulation Efficiency (%) = (Residual drug in the nanoparticle /Initial feeding amount of drug) × 100

Loading content and encapsulation efficiency of SPIONs were determined in triplicate using Atomic Absorption Spectrophotometer (AAS) (CTA-3000, ChemTech , UK) . HCl was used as a blank.

Size distribution and zeta potential

Hydrodynamic diameter, Poly Disparity Index (PDI), zeta potential and size distribution profile of nanoparticles were obtained with dynamic light scattering method. 1 mg of each polymeric formulation was dispersed in 1 mL of deionized water with bath sonication and analyzed with zetasizer (NANO-ZS, Malvern, UK). For SPIONs, 5 mg of nanoparticles were dispersed in 1 mL of chloroform.

Transmission electron microscopy

The particle size and morphology of the magnetic nanoparticles were observed by transmission electron microscopy (LEO 910, Zeiss, Germany). Lyophilized nanoparticles of SPION-PLGA-Gem were dispersed in ultrapure water with bath sonicator and SPIONs were dispersed in chloroform. The samples were deposited onto a copper grid (300 mesh) and left until the excess liquid was removed and then were dried under infrared light. The acceleration voltage was set to 100 kV for SPION and 80 kV for SPION-PLGA-Gem nanoparticles.

Atomic force microscopy

The surface morphology of SPION-PLGA-Gem nanoparticles was observed by Atomic Force Microscopy (AFM, model: Nano Wizard II NanoScience AFM, JPK Instruments Inc., Germany). The glass slide of microscope was washed with acetone and ethanol, and then was rinsed with ultrapure water and was dried. After cleaning, lyophilized nanoparticles were dispersed in ultrapure water with bath sonicator (0.1 mg/mL) and then were dispensed onto glass slide and left at room temperature until dried. The measurements were performed in the tapping mode and dehydrated state in air, and ACT cantilevers were used.

In-vitro Gemcitabine release

In-vitro release behavior of Gemcitabine from SPION-PLGA-Gem formulation was assessed in sink condition. 5 mg of formulation was reconstituted in 5 mL PBS (pH 7.4) and the solvent was placed at a hybridization oven (Brunswick Scientific CO., Inc., New Jersey, USA) at 37 ˚C, 25 rpm. At specified time intervals (2, 4, 8, and 12 h; 1, 2, 4 and 7 days), the sample was centrifuged (10 min, 14000 rpm) and 200 µL of supernatant was displaced with PBS. Then, the accumulative ratios of the released Gemcitabine were calculated as a function of time. The concentration of Gemcitabine in each sample was determined using UV-Vis spectrophotometer.

Cell line and cell culture

MCF-7 Breast cancer cell line (obtained from Pasteur Institute of Iran) was cultured in the RPMI medium supplemented with heat-inactivated fetal bovine serum (FBS) (10% vol/vol), penicillin (100 U/mL), and streptomycin (100 µg/mL). The cultures were incubated at 37 °C in a humidified atmosphere containing 5% CO2 (vol/vol). For experiments, the cells were used while they were in the exponential growth phase.

Toxicity of Gemcitabine and Nanoparticles

For in-vitro evaluation of toxicity of Gemcitabine and prepared formulations, MTT assay was used. Briefly, MCF-7 cells were seeded into 96-well plates at density of 1 × 104 cells/well. After 48 h incubation, different concentrations of Gemcitabine (0.01-25 µM) and their equivalent concentrations of the formulations (PLGA, SPION-PLGA, PLGA-Gem and SPION-PLGA-Gem) were dispersed in RPMI. Then the RPMI in each well was precisely replaced with the RPMI including the formulations. After 48-hours incubation, 20 µL MTT reagents in PBS (5 mg/mL) were added to each well and were incubated for 3.5 h at 37 ˚C. Then the medium was replaced with 100 µL of DMSO and the absorbance was measured with an ELISA microplate reader (TECAN infinite M200, Switzerland) at 570/630 nm wavelength. The percentage of viability (100×absorbance of test/absorbance of control) was calculated for each group. The viability (%) of the cells under treatment by Gemcitabine was also studied using 24 h MTT assays.

Statistical analysis

All the data were obtained using SPSS 16.0 statistical package. The results were reported as mean ± standard deviation (SD) of triplicates. Statistical differences for multiple groups were obtained using a one-way ANOVA and individual groups were compared with Student’s t-test. Probabilities of P < 0.05 were considered as significant.

Results and discussion

Recently, there is much attention dedicated to develop and characterize of materials at nanoscale for various and new applications. In this study, SPION and Gemcitabine were simultaneously encapsulated in PLGA ± PEG to form a multifunctional drug delivery system. Optimum size and encapsulation efficiency were considered with respect to the radiosensitization, hyperthermia, and diagnostic applications as well as the preparation parameters were investigated systematically. Additional to the above issues, physicochemical characteristics of the optimized nanoparticles were studied. Then SPION-PLGA and PLGA-Gem nanoparticles were prepared with the same optimized parameters and the toxicity of these nanoparticles was compared with Gemcitabine alone in human breast cancer cell line (MCF-7).

Optimization of preparation parameters of polymeric nanoparticles

In this study, for optimization of preparation parameters of nanoparticles, various applications such as hyperthermia (with ultrasound or RF waves), sonoporation, radiosensitization in radiotherapy and contrast enhancement of ultrasound and MR images were considered.

For final selection of the optimal preparation parameter of (SPION- PLGA-Gem) ± PEG nanoparticles, size and encapsulated efficiency (EE) were considered and the examined variables were the volume percentage of sucrose (as cryoprotectant); and weight fractions of Gemcitabine and SPION to the polymer. Moreover, the presence and absence of PEG was examined in order to improve the physicochemical properties of nanoparticles for in-vivo studies.

For selection of volume fractions, sonication time, washing and other parameters, the previous studies and experiments were taken into account.

Then, for better comparison of various formulations, weight fractions for (PLGA-Gem) ± PEG, (SPION-PLGA) ± PEG and PLGA ± PEG nanoparticles were selected similar to the (SPION-PLGA-Gem) ± PEG nanoparticles.

Optimization of formulation with sucrose

In order to evaluate the effect of sucrose in nanoparticles size, 0%, 1% and 3% sucrose per 20 mg of PLGA ± PEG were examined. As it is evident from the data in Table 1. 3% sucrose has considerable effect on the optimization of nanoparticle size. Additionally, there has no considerable deference in nanoparticle size between the 1% and 3% sucrose. Therefore, for evaluation of the other parameters, 1% sucrose per 20 mg of polymer was used to increase the weight fraction of nanoparticles in the final product.

Optimization of formulation with concentration of SPION

To optimize the formulation with SPION, different concentrations of SPION (2, 4 and 10 mg per 1 mL chloroform, equivalent with 0.08, 0.16 and 0.4 of SPION/PLGA) were used. From the data presented in Table 2. it can be seen that although the size of the nanoparticles at SPION concentration of 4 mg/mL is higher than 2 mg /mL, but both sizes of nanoparticles are in the desirable range (about 200 nm), and thus the concentration of 2 mg/mL was neglected. Additionally, since the loading content and encapsulation efficiency of SPION and Gem in concentration of 10 mg/mL is better than 4 mg/mL, the optimum concentration is 10 mg/mL

Optimization of formulation with weight ratio of Gem/polymer

For this purpose, two fractions of 0.04 and 0.08 were examined. Nanoparticles that were characterized in Table 3. were prepared at fixed conditions of 1% sucrose, 10 mg/mL of SPION/chloroform. As it can be seen in Table 3. weight fractions of 0.04 and 0.08 had no considerable effect on nanoparticle size and encapsulation efficiency, therefore to improve the loading content of Gemcitabine, the fraction of 0.04 was selected.

Addition of PEG to formulation

To evaluate the effect of PEG, in all the experiments, 20% of PLGA was replaced with PEG. According to the results that were listed in Table 2 and Table 3. The existence of PEG has no considerable effect on the size and encapsulation efficiency of nanoparticles.

Optimized parameters for preparation of SPION-PLGA-Gem nanoparticles

With respect to the previous results, for the SPION-PLGA-Gem formulation, the selected parameters included 25 mg of PLGA ± PEG in 1 mL dichloromethane, 1 mg Gem per 200 mL of deionized water (equivalent to Gem/polymer of 0.04), 10 mg SPION per 1 mL of chloroform (equivalent to SPION/polymer of 0.4) and 1% sucrose per 20 mg of PLGA ± PEG.As it was mentioned before, nanoparticles made from PEG-PLGA exhibit in-vivo long-circulation properties (20, 21). Therefore, for examination of in-vitro toxicity of the prepared nanoparticles, PEG was not used.

Table 1

Hydrodynamic diameter (Zave) and PDI of (PLGA-Gem-SPION) ± PEG nanoparticles obtained by zetasizer. The sucrose was considered as the dependent variable

PDI(Mean)Sizeave (nm)*(Mean ± SD)Sucrose(%)PEG(mg)SPION)mg/mL)PLGA(mg)mGemmPolymer
0.2389.0±1044.00510200.08
0.17178.5±9.61510200.08
0.158.3±170.23510200.08
0.1566.6±678.50010250.08
0.09173.4±0.51010250.08
0.053.1±171.23010250.08
Table 2

Hydrodynamic diameter (Zave), PDI and encapsulation efficiency of SPION and Gemcitabine in (PLGA-Gem-SPION) ± PEG nanoparticles. The SPION and PEG were considered as dependent variables. Zave and PDI were obtained by zetasizer

PDI*Mean*Sizeave(nm)Mean±SD%EE (Gem) Mean±SD%EE(SPION)Ŧ Mean±SDSPION)mg/mL)mGemmPolymerPLGAPEGSucrose(%)
0.17178.5±9.617.1±0.40.6±40.2100.082051
0.09173.4±0.513.8±0.33.4±44.9100.082501
0.15160.0±4.115.2±1.33.2±45.140.082051
0.10163.2±1.211.6±0.95.1±47.340.082501
0.155.2±165.315.2±1.63.1±45.120.082051
0.103.4±161.111.6±2.35.1±47.320.082501

Obtained by UV-Vis spectrophotometer.

Obtained by atomic absorption spectrophotometer

Table 3

Hydrodynamic diameter (Zave), PDI and encapsulation efficiency of SPION and Gemcitabine in (PLGA-Gem-SPION) ± PEG nanoparticles. The Gemcitabine ratio and PEG were considered as dependent variables. Zave and PDI were obtained by zetasizer

PDI*Mean*Sizeave(nm)Mean±SD%EE (Gem) Mean±SD%EE(SPION)Ŧ Mean±SDSPION)mg/mL)mGemmPolymerPLGAPEGSucrose(%)
0.088.0±174.016.1±2.047.7±2.6100.042051
0.17178.5±9.617.1±0.40.6±40.1100.082001
0.0810.0±180.016.0±1.048.2±2.1100.042551
0.09173.4±0.513.8±0.33.4±44.9100.082501

Obtained by UV-Vis Spectrophotometer.

Obtained by atomic absorption spectrophotometer

Table 4

Size, zeta potential and PDI of nanoparticles with optimum preparation parameters

FormulationZave(nm)**(mean±SD)Size (nm)(TEM)PDI*(mean±SD)Zeta potential (mV)(mean±SD)
SPION2.2±20.17.0±0.50.20±0.05+20.2±2.0
PLGA190.6±8.6-0.03±0.01-15.3±0.5
SPION- PLGA170.3±4.6-0.16±0.04-12.1±1.0
PLGA-Gem175.2±8.3-0.05±0.02-14.2±1.1
SPION-PLGA-Gem180.2±10.3180.0±20.00.08±0.02-13.3±1.0

Poly Disperse Index (PDI), Zave and zeta potential (mV) were obtained by DLS.

Table 5

Hydrodynamic diameter (nm) of polymeric nanoparticles (by DLS) and average size (nm) of SPION (by TEM) in this study compared with previous studies

FormulationThis study(mean ± SD)Other studies*References
SPION (TEM)7.0±0.54-20(37-41)
PLGA-SPION170.0±4.6293-110(38, 39, 42)
PLGA-Drug-50-190(18, 43)
PLGA-Gem175.0±8.3132-206(1, 3, 36, 37)
SPION-PLGA-Drug180.0±10.0200-300(40, 44)

Other studies with approximately similar synthesis and preparation methods

Table 6

Loading content and encapsulation efficiency of Gem and (or) SPION in formulations. Encapsulation efficiency of SPION and Gemcitabine were determined in triplicate using atomic absorption spectrophotometer and UV-Vis spectrophotometer, respectively

FormulationEncapsulation efficiency (%)
Loading content(%)
Gem( UV-Vis)SPION(AAS)GemSPION
SPION-PLGA-50.1±1.1-28.6
PLGA-Gem13.2±1.3-3. 8-
SPION-PLGA-Gem16.1±2.248.2±2.12.827.8
Table 7

Enhancement ratios and survival (%) of MCF-7 cells in various treatment groups after 48 h incubation. The concentration of formulations is equivalent to IC50 of Gemcitabine (10.3 µM

FormulationSurvival (%)Enhancement ratioP-value*
PLGA-SPION93.1±1.2--
Gem50.0±0.01.00-
PLGA-Gem32.7±1.11.530.015
SPION-PLGA-Gem26.2±2.31.890.006

P-values are calculated compared to Gemcitabine group

TEM image of SPIO nanoparticles (a), TEM image of SPION-PLGA-Gem nanoparticles (b).The samples were deposited onto a copper grid (300 meshes). The acceleration voltage was set to 100 kV for SPION and 80 kV for SPION-PLGA-Gem nanoparticles

TEM image of SPIO nanoparticles (a), TEM image of SPION-PLGA-Gem nanoparticles (b).The samples were deposited onto a copper grid (300 meshes). The acceleration voltage was set to 100 kV for SPION and 80 kV for SPION-PLGA-Gem nanoparticles

Figure 1

AFM image of SPION-PLGA-Gem nanoparticles. Lyophilized nanoparticles (100 µg) were dispersed in ultrapure water with bath sonicator (0.1 mg/ml) and were dispensed onto the glass slide of microscope

AFM image of SPION-PLGA-Gem nanoparticles. Lyophilized nanoparticles (100 µg) were dispersed in ultrapure water with bath sonicator (0.1 mg/ml) and were dispensed onto the glass slide of microscope

Figure 2

Size distribution of nanoparticles obtained by AFM, SPIONs (a), SPION-PLGA-Gem nanoparticles (b

Size distribution of nanoparticles obtained by AFM, SPIONs (a), SPION-PLGA-Gem nanoparticles (b

Figure 3

In-vitro cumulative release of Gemcitabine from SPION-PLGA-Gem nanoparticles at the specified intervals (2, 4, 8, 12 hours; 1, 2, 4 and 7 days) in PBS (7.4 pH). The data were obtained by UV-Vis spectrophotometry

In-vitro cumulative release of Gemcitabine from SPION-PLGA-Gem nanoparticles at the specified intervals (2, 4, 8, 12 hours; 1, 2, 4 and 7 days) in PBS (7.4 pH). The data were obtained by UV-Vis spectrophotometry

Figure 4

Survival (%) of MCF-7 cells treated by Gemcitabine after 24 and 48-hours incubation. The serial concentrations of Gemcitabine are 0.01-25 µM

Survival (%) of MCF-7 cells treated by Gemcitabine after 24 and 48-hours incubation. The serial concentrations of Gemcitabine are 0.01-25 µM

Figure 5

Survival (%) of MCF-7 cells of various treatment groups after 48-hours incubation. The concentrations of formulations are equivalent the concentration of 0.01 µM to 10.3 µM of Gemcitabine

Survival (%) of MCF-7 cells of various treatment groups after 48-hours incubation. The concentrations of formulations are equivalent the concentration of 0.01 µM to 10.3 µM of Gemcitabine

Figure 6

Survival (%) of MCF-7 cells of various treatment groups after 48-hours incubation. The concentration of formulations is equivalent to IC50 of Gemcitabine (10.3 µM). *p≤0.05 compared to Gemcitabine group, **p≤0.01 compared to Gemcitabine group

Survival (%) of MCF-7 cells of various treatment groups after 48-hours incubation. The concentration of formulations is equivalent to IC50 of Gemcitabine (10.3 µM). *p≤0.05 compared to Gemcitabine group, **p≤0.01 compared to Gemcitabine group

Figure 7

Physicochemical properties of nanoparticles

Morphology and size distribution

Morphology of prepared nanoparticles obtained by TEM and AFM in Figure 1 and 2. illustrates that SPIONs prepared by chemical coprecipitation method are spherical with uniform distribution and SPIO-PLGA-Gem nanoparticles prepared by a double emulsion method are also have nearly spherical shape and is uniformly distributed. Entrapped SPIONs in these nanoparticles are obvious as dark spherical points.

Size, size distribution and zeta potential

Hydrodynamic diameter, Poly Disparity Index (PDI), zeta potential and size distribution profile of nanoparticles were obtained by dynamic light scattering (DLS) method. According to Table 4. the average hydrodynamic diameter of these nanoparticles is 20.1 ± 2.2 nm with PDI of 0.20 ± 0.05. The size of SPIONs that was obtained by TEM is 7.0 ± 0.5 nm. Zeta potential of these nanoparticles is 20.2 ± 2.0 mV. These nanoparticles have narrow size distribution (Figure 3 (a)).

As listed in Table 4. the average size of SPION-PLGA-Gem nanoparticles that was obtained by TEM is 180.0 ± 20.0 nm. The average hydrodynamic diameter of these nanoparticles obtained by DLS is 180.2 ± 10.3 nm with PDI of 0.08 ± 0.02. Zeta potential of these nanoparticles is -13.3 ± 1.0 mV. SPION-PLGA-Gem nanoparticles disperses easily in water and be collected by permanent magnet. As it illustrated in Figure 3 (b). the size distribution of SPION-PLGA-Gem nanoparticles is Gaussian, narrow, and symmetrical.From the data listed in Table 4. the average Hydrodynamic diameters of polymeric nanoparticles with minor differences were less than 200 nm. The size of the PLGA nanoparticles (without drug and SPION), is slightly more than all other provided nanoparticles (190 ± 8.6). This indicates that the existence of SPION in the formulation, on the one hand, increases PDI and on the other hand, may not have a considerable impact on the size and make slight adjustments to it. This may be due to the role of the SPION nanoparticles in stability and prevention of aggregation of polymeric nanoparticles.

In Table 5. the sizes of prepared nanoparticles are compared with the sizes of the same nanoparticles provided in the other studies. As it can be seen, the sizes of these nanoparticles are in an appropriate range, compared with the other studies using similar preparation methods.

Drug loading and entrapment efficiency

As can be seen from Table 6. the SPION encapsulation efficiency, using AAS method, is about 50%. Of course this amount is affected by the loading content of SPIONs in the polymeric nanoparticles. SPION loading content in provided polymeric nanoparticles is about 28%. Gemcitabine loading capacity in polymeric nanoparticles is between 2.8% for the SPION-PLGA-Gem formulation and 3.8% for the PLGA-Gem formulation.

Efficiency of Gemcitabine encapsulation is 16.1 ± 2.2 (%) and 13.2 ± 1.3 (%) in these formulations, respectively.

Higher performance of SPION encapsulation (4 folds) in SPION-PLGA-Gem formulation compared to Gemcitabine may be effective for radiosensitivity and imaging purposes. The cause of the issue is that in these applications, concentrations of Gemcitabine with minimal toxicity are used, while considering the lower toxicity of SPION compared to Gemcitabine, there is no special restrictions on the use of SPION compared with Gemcitabine. Using higher density of SPION leads to the effectiveness of diagnosis and treatment.

Therefore, this amount of the difference in Encapsulation Efficiency between SPION and Gemcitabine appears to be favorable for application purposes.

In-vitro release of Gemcitabine

Due to chemical instability and poor cell harvest, Gemcitabine has a very short half-life in plasma after intravenous injection (25). Therefore, it should be used with high doses leading to high systemic toxicity (1, 3). To solve this problem, in the past decades, nanotechnology has an improvement, and has emerged as a basis for the treatment of a wide range of different tumors. Nanotechnology leads to a prolongation of the release and increasing the entrance of drug into the cell (1). Nano platforms increase anti-tumor effects with negligible toxicity and causes controlled transfer and accumulation in tumor area and protection of drug molecules against biodegradability and plasma clearance (2).

In this study, PLGA nanoplatforms were used. The advantages of this polymer could be biodegradability, biocompatibility, decreasing their systemic side effects, facilitating intratumoral encapsulation, rapid clearance from the biological system and high efficiency of drugs transmission and transportation (17, 18, 26). Therefore, they have been used in many micro-formulations and nanoparticles (27-30). For example, fluorouracil (31), doxorubicin (7), docetaxel (32, 33), paclitaxel (34, 35) and cisplatin (20) could be mentioned.

Following the physicochemical characterization of NPs, in-vitro Gemcitabine release profile from SPION-PLGA-Gem NPs has been conducted in a PBS solution at pH 7.4. As illustrated in Figure 4. it can be seen that in the first 24 h, release rate grows with a slight slope and reaches more than 60% after 48 h. After this time the growth of the curve is very slight and slow. Therefore, the time of 50% release (T1/2) of about 18 h implies the drug release from the controlled drug delivery system is controllable and sustains in the natural conditions (pH 7.4). Therefore, it is expected that the provided nanoplatforms are suitable for controlled transfer, accumulation in tumor area and protecting of drug molecules from biodegradability and plasma clearance.

The release curve shows that in 48 h, more than 60 percent of the drug is released from the formulation and then the trend of release growth will be slow.

Toxicity of Gemcitabine hydrochloride and nanoparticles

In this study with the aim of in-vivo applications, nanoparticles of SPION-PLGA-PEG-Gem were also prepared and the results showed that addition of PEG to PLGA has no considerable effect on physical properties of nanoparticles (Table 4), but for in-vitro toxicity experiments, nanoparticles without PEG were used.

The viability (%) of the cells under treatment by Gemcitabine (with concentration between 0.01 µM to 25 µM) was studied using 24 h and 48 h MTT assays. As it can be seen in Figure 5. the repeatability of the toxicity data in 48 h incubation is better than the 24 h incubation. Moreover, According to the slope of the release curve in the first 24 h and slowing the release curve growth after 48 h (Figure 4), it can be concluded that to assess the toxicity of the nanoparticles, incubation time of 48 h is more appropriate and therefore considered for evaluation of toxicity of nanoparticles.

After determining the range of treatment concentration of Gemcitabine, the MCF7 cells were treated by different formulations with the same procedure, in the range of concentrations equivalent to the concentrations (0.01 μM to 10.3 μM) of Gemcitabine (released in 48 h).

Figure 6 illustrates the survival of MCF-7 cells under various treatment groups by nanomolar equivalent concentrations of Gemcitabine with 48-hours incubation using MTT assay. This figure obviously shows the effectiveness of the treatment with SPION-PLGA-Gem compared to Gemcitabine and the other nanoparticles, especially at higher concentrations.

The range of inhibitory concentration of 10% (IC10) for Gemcitabine is about 10 nM. The toxicity of the other formulations containing 10 nM Gemcitabine is relatively equivalent to the toxicity of 10 nM Gemcitabine. SPION-PLGA nanoparticles with very higher concentrations (equivalent to 25 μM of Gemcitabine in other formulations) have no considerable toxicity (less than 10% toxicity). This suggests that the use of SPION in different formulations has a great advantage for therapeutic applications (hyperthermia and radiosensitization) or diagnostic applications (as a contrast agent in MR and ultrasound imaging). According to Figure 6. treatment with polymeric nanoparticles considerably had better result than Gemcitabine. The survivals of cell treated by concentration of formulations that were equivalent to IC50 of Gemcitabine were listed in Table 7. The survivals were 26.5% and 32.7% for SPIO-PLGA-Gem and PLGA-Gem respectively (that were equivalent to DER of 1.89 and 1.53).As illustrated in Figure 7. statistical differences between these groups are significant (p-values of 0.006 and 0.015 for SPIO-PLGA-Gem and PLGA-Gem groups compared with Gemcitabine group). It means the good treatment efficiency of formulations for MCF7 cells.In this study nanoparticles of SPION-PLGA-PEG-Gem were also prepared and the results showed that addition of PEG to PLGA had no considerable effect on physical properties of nanoparticles (Zave = 174.0 ± 8.0 nm, PDI = 0.08 ± 0.03 and zeta potential = 15 ± 1.6 mV) but for in-vitro experiments, nanoparticles without PEG were used.

Conclusion

In the present study, a novel Gemcitabine loaded super paramagnetic PLGA-Iron Oxide multifunctional drag delivery system was developed. This optimization was designed based on applications such as radio sensitization, hyperthermia and ultrasound and MR imaging by contrast agents. By improving the issues related to the instability of Gemcitabine, an appropriate system was obtained for transfer and enhancement of antitumor activity of Gemcitabine.

Regarding to the studies on the use of SPIONs for MR and US imaging purposes, it seems that these nanoparticles are easily able to meet the goals in these modalities. However, the use of magnetic nanoparticles in hyperthermia will provide a better effectiveness of Gemcitabine in inhibition of tumor cells.

Nanoparticles such as SPIO-PLGA-Gem that their efficiency have proved for diagnosis and treatment and drug delivery objectives, may be worthy as subjects for future studies. Future evaluations include in-vitro and in-vivo investigation of radiosensitization and other applications of these nanoparticles.

Acknowledgements

References

  • 1.

    Martín-Banderas L, Sáez-Fernández E, Holgado MÁ, Durán-Lobato MM, Prados JC, Melguizo C, Arias JL. Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing® for efficient antitumor activity. Int. J. Pharm. 2013;443:103-9. [PubMed ID: 23299085].

  • 2.

    Reddy LH, Couvreur P. Novel approaches to deliver gemcitabine to cancers. Current Pharm. Design. 2008;14:1124-37.

  • 3.

    Papa A-L, Basu S, Sengupta P, Banerjee D, Sengupta S, Harfouche R. Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells. BMC Cancer. 2012;12:419. [PubMed ID: 22998550].

  • 4.

    Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature. 2005;436:568-72. [PubMed ID: 16049491].

  • 5.

    Beletsi A, Leontiadis L, Klepetsanis P, Ithakissios D, Avgoustakis K. Effect of preparative variables on the properties of poly (dl-lactide-co-glycolide)–methoxypoly (ethyleneglycol) copolymers related to their application in controlled drug delivery. Int. J. Pharm. 1999;182:187-97. [PubMed ID: 10341308].

  • 6.

    Křížová J, Španová A, Rittich B, Horák D. Magnetic hydrophilic methacrylate-based polymer microspheres for genomic DNA isolation. J. Chrom. 2005;1064:247-53.

  • 7.

    Yoo HS, Lee KH, Oh JE, Park TG. In-vitro and in-vivo anti-tumor activities of nanoparticles based on doxorubicin–PLGA conjugates. J. Control. Release. 2000;68:419-31. [PubMed ID: 10974396].

  • 8.

    Kumar KS, Jaikumar V. Gold and iron oxide nanoparticle-based ethylcellulose nanocapsules for cisplatin drug delivery. Iran. J. Pharm. Res. 2011;10:415. [PubMed ID: 24250373].

  • 9.

    Chen B, Cheng J, Shen M, Gao F, Xu W, Shen H, Ding J, Gao C, Sun Q, Sun X. Magnetic nanoparticle of Fe3O4 and 5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin in leukemia cells. Int. J. Nanomed. 2009;4:65.

  • 10.

    Wang J, Chen Y, Chen B, Ding J, Xia G, Gao C, Cheng J, Jin N, Zhou Y, Li X. Pharmacokinetic parameters and tissue distribution of magnetic Fe3O4 nanoparticles in mice. Int. J. Nanomed. 2010;5:861.

  • 11.

    Xie J, Huang J, Li X, Sun S, Chen X. Iron oxide nanoparticle platform for biomedical applications. Current Med. Chem. 2009;16:1278-94.

  • 12.

    Neuberger T, Schöpf B, Hofmann H, Hofmann M, Von Rechenberg B. Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system. J. Mag. Mag. Material. 2005;293:483-96.

  • 13.

    Lee S-J, Jeong J-R, Shin S-C, Kim J-C, Chang Y-H, Chang Y-M, Kim J-D. Nanoparticles of magnetic ferric oxides encapsulated with poly (D, L latide-co-glycolide) and their applications to magnetic resonance imaging contrast agent. J. Mag. Mag. Material. 2004;272:2432-3.

  • 14.

    Silva AC, Oliveira TR, Mamani JB, Malheiros S, Malavolta L, Pavon LF, Sibov TT, Amaro Jr E, Tannus A, Vidoto E. Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in glioma treatment. Int. J. Nanomed. 2011;6:591-603.

  • 15.

    Klein S, Sommer A, Distel LV, Neuhuber W, Kryschi C. Superparamagnetic iron oxide nanoparticles as radiosensitizer via enhanced reactive oxygen species formation. Biochem. Biophys. Res. Commun. 2012;425:393-7. [PubMed ID: 22842461].

  • 16.

    Arnold MM, Gorman EM, Schieber LJ, Munson EJ, Berkland C. NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J. Control. Release. 2007;121:100-9. [PubMed ID: 17604870].

  • 17.

    Cheng F-Y, Wang SP-H, Su C-H, Tsai T-L, Wu P-C, Shieh D-B, Chen J-H, Hsieh PC-H, Yeh C-S. Stabilizer-free poly (lactide-co-glycolide) nanoparticles for multimodal biomedical probes. Biomaterials. 2008;29:2104-12. [PubMed ID: 18276001].

  • 18.

    Jin C, Bai L, Wu H, Tian F, Guo G. Radiosensitization of paclitaxel, etanidazole and paclitaxel+ etanidazole nanoparticles on hypoxic human tumor cells in-vitro. Biomaterials. 2007;28:3724-30. [PubMed ID: 17509678].

  • 19.

    Amjadi I, Rabiee M, Hosseini M-S. Anticancer activity of nanoparticles based on PLGA and its co-polymer: in-vitro evaluation. Iran. J. Pharm. Res. 2013;12:623. [PubMed ID: 24523742].

  • 20.

    Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas A, Ithakissios D. PLGA–mPEG nanoparticles of cisplatin: in-vitro nanoparticle degradation, in-vitro drug release and in-vivo drug residence in blood properties. J. Control. Release. 2002;79:123-35. [PubMed ID: 11853924].

  • 21.

    Chen Y, Wang F, Benson H. Effect of formulation factors on incorporation of the hydrophilic peptide dalargin into PLGA and mPEG-PLGA nanoparticles. Peptide Science. 2008;90:644-50. [PubMed ID: 18459172].

  • 22.

    Duan Y, Sun X, Gong T, Wang Q, Zhang Z. Preparation of DHAQ-loaded mPEG-PLGA-mPEG nanoparticles and evaluation of drug release behaviors in-vitro/in-vivo. J. Mat. Sci. Mat. Med. 2006;17:509-16.

  • 23.

    Park J, Fong PM, Lu J, Russell KS, Booth CJ, Saltzman WM, Fahmy TM. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomed. Nanotech. Biol. Med. 2009;5:410-8.

  • 24.

    Massart R. Preparation of aqueous magnetic liquids in alkaline and acidic media. IEEE Transaction. Magnet. 1981:1247-8.

  • 25.

    Dueñas-Gonzalez A, Coronel J, Cetina L. Pharmacokinetic evaluation of gemcitabine hydrochloride for the treatment of cervical cancer. Expert Opin. Drug Metab. Toxicol. 2011;7:1601-12. [PubMed ID: 21955161].

  • 26.

    Gu B, Burgess DJ. Prediction of dexamethasone release from PLGA microspheres prepared with polymer blends using a design of experiment approach. Int. J. Pharm. 2015;495:393-403. [PubMed ID: 26325309].

  • 27.

    A Holgado M, Alvarez-Fuentes J, Fernández-Arévalo M, L Arias J. Possibilities of poly (D, L-lactide-co-glycolide) in the formulation of nanomedicines against cancer. Current Drug Target. 2011;12:1096-111.

  • 28.

    Garg AK, Buchholz TA, Aggarwal BB. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxidants and redox signaling. 2005;7:1630-47. [PubMed ID: 16356126].

  • 29.

    Kumar N, Ravikumar MN, Domb A. Biodegradable block copolymers. Adv. Drug Delivery Rev. 2001;53:23-44.

  • 30.

    Mahboubian A, Hashemein SK, Moghadam S, Atyabi F, Dinarvand R. Preparation and in-vitro evaluation of controlled release PLGA microparticles containing triptoreline. Iran. J. Pharm. Res. 2010;9:369. [PubMed ID: 24381601].

  • 31.

    Blanco M, Sastre R, Teijon C, Olmo R, Teijon J. 5-Fluorouracil-loaded microspheres prepared by spray-drying poly (D, L-lactide) and poly (lactide-co-glycolide) polymers: characterization and drug release. J. Microencap. 2005;22:671-82.

  • 32.

    Chan JM, Zhang L, Yuet KP, Liao G, Rhee J-W, Langer R, Farokhzad OC. PLGA–lecithin–PEG core–shell nanoparticles for controlled drug delivery. Biomaterials. 2009;30:1627-34. [PubMed ID: 19111339].

  • 33.

    Koopaei MN, Khoshayand MR, Mostafavi SH, Amini M, Khorramizadeh MR, Tehrani MJ, Atyabi F, Dinarvand R. Docetaxel loaded PEG-PLGA nanoparticles: optimized drug loading, in-vitro cytotoxicity and in-vivo antitumor effect. Iran. J. Pharm. Res. 2014;13:819. [PubMed ID: 25276182].

  • 34.

    Chakravarthi SS, De S, Miller DW, Robinson DH. Comparison of anti-tumor efficacy of paclitaxel delivered in nano-and microparticles. Int. J. Pharm. 2010;383:37-44. [PubMed ID: 19747969].

  • 35.

    Lu J, Chuan X, Zhang H, Dai W, Wang X, Zhang Q. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in-vitro and in-vivo. Int. J. Pharm. 2014;471:525-35. [PubMed ID: 24858391].

  • 36.

    Aggarwal S, Gupta S, Pabla D, Murthy R. Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer. Cancer Nanotech. 2013;4:145-57.

  • 37.

    Zhu S, Li X, Kumar A, Cui Z. A nanoparticle depot formulation of 4-(N)-stearoyl gemcitabine shows a strong anti-tumour activity. J. Pharm. Pharm. 2013;65:236-42.

  • 38.

    Akbarzadeh A, Mikaeili H, Zarghami N, Mohammad R, Barkhordari A, Davaran S. Preparation and in-vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymers. Int. J. Nanomed. 2012;7:511.

  • 39.

    Hwang JH, Noh YW, Choi JH, Noh JR, Kim YH, Gang GT, Kim KS, Park HS, Lim YT, Moon H. In-vivo imaging of islet transplantation using PLGA nanoparticles containing iron oxide and indocyanine green. Magnet. Resonance Med. 2014;71:1054-63.

  • 40.

    Jia Y, Yuan M, Yuan H, Huang X, Sui X, Cui X, Tang F, Peng J, Chen J, Lu S. Co-encapsulation of magnetic Fe3O4 nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery. Int. J. Nanomed. 2012;7:1697.

  • 41.

    Verma NK, Crosbie-Staunton K, Satti A, Gallagher S, Ryan KB, Doody T, McAtamney C, MacLoughlin R, Galvin P, Burke CS. Magnetic core-shell nanoparticles for drug delivery by nebulization. J. Nanobiotech. 2013:11.

  • 42.

    Tang KS, Hashmi SM, Shapiro EM. The effect of cryoprotection on the use of PLGA encapsulated iron oxide nanoparticles for magnetic cell labeling. Nanotechnology. 2013;24:125101. [PubMed ID: 23459030].

  • 43.

    Jin C, Bai L, Wu H, Teng Z, Guo G, Chen J. Cellular uptake and radiosensitization of SR-2508 loaded PLGA nanoparticles. J. Nanopart. Res. 2008;10:1045-52.

  • 44.

    Schleich N, Sibret P, Danhier P, Ucakar B, Laurent S, Muller RN, Jérôme C, Gallez B, Préat V, Danhier F. Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging. Int. J. Pharm. 2013;447:94-101. [PubMed ID: 23485340].